Scientists from Tulane University in the US, have developed a drug, called AQ-13, which can effectively treat malaria and can also help to fight strains of the deadly infection that are resistant to existing treatments. Initially, public health experts have warned that the parasite Plasmodium falciparum is developing drug resistance qualities and new medications are required to deal with it. Eventually, in a successful clinical trial on human patients, AQ-13 was able to clear Plasmodium falciparum within a week. It even matched with the effectiveness of the most widely used treatment regimen. The trial was performed on 66 adult men with uncomplicated malaria. Half were treated with AQ-13 and other half with artemether and lumefantrine. Both the groups had similar cure rates. Initially, chloroquine was used to treat malaria until the parasite developed resistance towards it. Currently, artemether and lumefantrine combination is used for the treatment but resistance has also been recorded in some countries. Around 200 million people around the world gets infected annually out of which 400,000 deaths happen due to the parasite. Researchers are planning to expand the trials to more participants before launching.